DrugPatentWatch Database Preview

Celgene Company Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?

CELGENE has six approved drugs.

There are thirty-seven US patents protecting CELGENE drugs.

There are six hundred and thirteen patent family members on CELGENE drugs in fifty-one countries and twenty-one supplementary protection certificates in twelve countries.

Summary for Celgene

International Patents:	613
US Patents:	37
Tradenames:	6
Ingredients:	6
NDAs:	6
Patent Litigation for Celgene:	See patent lawsuits for Celgene
PTAB Cases with Celgene as patent owner:	See PTAB cases with Celgene as patent owner

Drugs and US Patents for Celgene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011		RX	Yes	No
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006		RX	Yes	No	8,315,886
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-003	Feb 8, 2013		RX	Yes	No	6,755,784
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003		RX	Yes	No	6,561,977
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011		RX	Yes	No
Celgene	VIDAZA	azacitidine	POWDER;INTRAVENOUS, SUBCUTANEOUS	050794-001	May 19, 2004	AP	RX	Yes	Yes

Expired US Patents for Celgene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	7,119,106
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	6,555,554
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	6,281,230
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	6,555,554
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-002	Feb 8, 2013	6,561,976
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	6,235,756

Paragraph IV (Patent) Challenges for CELGENE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	1 mg, 2 mg, 3 mg and 4 mg		2017-02-08
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	50 mg and 100 mg		2006-12-18
	Capsules	150 mg		2014-02-03
	Capsules	25 mg		2010-07-12
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	200 mg		2006-09-25
	Injection	10 mg/vial		2013-11-05

International Patents for Celgene Drugs

Country	Patent Number	Estimated Expiration
Denmark	1505973
Poland	2800743
Taiwan	200817004
European Patent Office	2087891
China	101816626
European Patent Office	1956017

Supplementary Protection Certificates for Celgene Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2105135	1590004-6	Sweden		PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
2105135	00140	Estonia
2105135	C300717	Netherlands		PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
2105135	5/2015	Austria		PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805
2105135	92642	Luxembourg		PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805
0925294	07C0056	France		PRODUCT NAME: LENALIDOMIDE; REGISTRATION NO/DATE: EU/1/07/391/001-004 20070618

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Celgene
• Celgene Corp